Physician profile
Diane E Turner
NPI 1205484565
$4,331.04
in general payments reported to CMS, 2019-2025
27 companies · $616 in 2025
The $616 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $726 · 2022: $665 · 2023: $974 · 2024: $1,349 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,932 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,931.63 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $971.25 | 2021-2025 | |
| Novo Nordisk INC | $814.19 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $636.55 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $627.32 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $291.48 | 2023-2025 | |
| Amarin Pharma, INC. | $122.56 | 2021-2022 | |
| Glaxosmithkline, LLC. | $122.53 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $84.66 | 2023-2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $82.55 | 2022-2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $80.96 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.49 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.66 | 2023-2024 | Xifaxan |
| Axsome Therapeutics, INC. | $56.46 | 2025 | Symbravo |
| Azurity Pharmaceuticals, INC. | $56.17 | 2023-2024 | Edarbi, Edarbi |
| Exact Sciences Corporation | $46.77 | 2024-2025 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $29.02 | 2023 | Barostim Neo System |
| Otsuka America Pharmaceutical, INC. | $28.76 | 2025 | Rexulti |
| Amgen INC. | $21.03 | 2024 | Otezla, Repatha |
| Dexcom, INC. | $19.53 | 2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $16.46 | 2024 | Xyosted |
| Galderma Laboratories, L.P. | $16.35 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.00 | 2022 | |
| Genentech USA, INC. | $14.54 | 2021 | |
| Philips North America LLC | $14.28 | 2024 | (Ck6) Holter |
| Cranial Technologies, INC | $14.06 | 2021 | |
| Astellas Pharma US INC | $13.94 | 2024 | Veozah |
| Tolmar, INC. | $13.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.